Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Samsung Bioepis Forms Novel Biologics JV with Takeda Pharma

publication date: Aug 22, 2017

Samsung Bioepis, a division of Samsung Biologics, announced a joint venture with Japan's Takeda Pharma to develop novel biologic drugs. The JV's first project will be TAK-671, a candidate aimed at severe acute pancreatitis. Samsung Biologics has two divisions: a biologics CMO operation, and Samsung Bioepis, a company formed by Samsung and Biogen. Until now, Bioepis has been developing biosimilars, but the Takeda agreement will take Bioepis into novel drug development for the first time. One year ago, Samsung Biologics staged a $2 billion IPO on the Korean market. More details....

Stock Symbols: (KS: 207940) (TYO: 4502) (NSDQ: BIIB)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.